<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This was a prospective clinical trial conducted at Khartoum Fertility Center, during the period June 2002 to February 2005 to investigate the efficacy of unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> and low-dose aspirin as prophylaxis against pregnancy loss in 58 pregnant Sudanese women with recurrent (&gt; or = 3) <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> associated with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>Three (5.1%) patients had early <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e>, three (5.1%) patients developed <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">pre-eclamptic toxaemia</z:e> and forty-seven (81%) of the 58 patients had cesarean delivery </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-seven (81%) women had live births and 8 (13.8%) had <z:hpo ids='HP_0001622'>preterm deliveries</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Eight (13.8%) of the neonates were admitted to the intensive care unit for various reasons </plain></SENT>
<SENT sid="4" pm="."><plain>There were 6 (10.3%) perinatal <z:hpo ids='HP_0011420'>deaths</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> of them were due to <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>None of the patients developed thromboembolic episode </plain></SENT>
<SENT sid="6" pm="."><plain>There was no maternal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The rate of live birth in this study was consistent with the previous reports </plain></SENT>
<SENT sid="8" pm="."><plain>This was a none controlled study; thus controlled clinical trials using low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> are urgently needed </plain></SENT>
</text></document>